Drugs / Ropivacaine Hydrocloride
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT03339284 Comparator | Dec 2017 → Dec 2022 | — | Tampere University Hospital | Unknown | No outcome recorded |
| — | NCT07449442 Comparator | Mar → May 2026 overdue | osteoarthritis, knee | Poznan University of Medical Sciences | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ropivacaine Hydrocloride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07449442 ↗ |
| Route | Other | “Single sided US-guided QLB using ropivacaine 3,75 mg/ml 20 ml” NCT03339284 ↗ |